miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma

• Published in: Cancer research (Chicago, Ill.) Vol. 78; no. 4; pp. 1017 - 1030
• Main Authors: Díaz-Martínez, Marta, Benito-Jardón, Lucía, Alonso, Lola, Koetz-Ploch, Lisa, Hernando, Eva, Teixidó, Joaquin
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research, Inc 15-02-2018
• Subjects: AKT protein; Cancer; Clinical outcomes; Drug resistance; Ectopic expression; Emergence; Inhibitors; MAP kinase; Melanoma; miRNA
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.can-17-1318

Melanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic benefits but the common emergence of drug resistance remains a challenge. We generated A375 melanoma cells resistant to vemurafenib with the goal of investigating changes in miRNA expression patterns that might contribute to resistance. Increased expression of miR-204-5p and miR-211-5p occurring in vemurafenib-resistant cells was determined to impact vemurafenib response. Their expression was rapidly affected by vemurafenib treatment through RNA stabilization. Similar effects were elicited by MEK and ERK inhibitors but not AKT or Rac inhibitors. Ectopic expression of both miRNA in drug-naïve human melanoma cells was sufficient to confer vemurafenib resistance and more robust tumor growth
Conversely, silencing their expression in resistant cells inhibited cell growth. Joint overexpression of miR-204-5p and miR-211-5p durably stimulated Ras and MAPK upregulation after vemurafenib exposure. Overall, our findings show how upregulation of miR-204-5p and miR-211-5p following vemurafenib treatment enables the emergence of resistance, with potential implications for mechanism-based strategies to improve vemurafenib responses.
Identification of miRNAs that enable resistance to BRAF inhibitors in melanoma suggests a mechanism-based strategy to limit resistance and improve clinical outcomes.
.